Table of Contents  

Madasu, Rana, Humad, Banat, and Al Jassmi: Rare complications of severe mucositis and psychosis with levetiracetam in an Emirati child with acute lymphoblastic leukaemia


Acute management of seizures is crucial if permanent neurological sequelae are to be prevented. In children with cancer, antiepileptic medication has been preferred because its interaction with chemotherapy is minimal.

Levetiracetam is a pyrrolidine derivative antiepileptic drug, which is chemically different from all other anticonvulsant agents. It has a novel mechanism of action that does not involve inhibitory and excitatory neurotransmission. Levetiracetam works by binding SV2A, an integral membrane protein present on synaptic vesicles, preventing synaptic vesicle release,1 thereby impeding conduction across the synapse. Studies have demonstrated that intravenous levetiracetam has a favourable safety and pharmacokinetic profile, and it has been shown to be consistent with orally administered levetiracetam in adult subjects.2,3

Weinstock et al.4 conducted an open-label, single-arm, multicentre, safety, tolerability and pharmacokinetic study of intravenous levetiracetam in children with epilepsy. The 52 subjects enrolled in the study ranged in age from 1 month to 16 years. No significant adverse events were reported and the drug was well tolerated in this population.

Multiple case reports, case series and retrospective studies focusing on children have reported the efficacy and tolerability of intravenous levetiracetam in acute seizure management, both as adjunctive treatment and as monotherapy.

Levetiracetam has also been used for busulfan-induced seizure prophylaxis in children undergoing haematopoietic stem cell transplantation.5

Case history

We report on a 10-year-old Emirati boy who presented with a mediastinal mass and signs of superior vena cava syndrome. Investigations showed that he had T-cell acute lymphoblastic leukaemia and ALL-BFM 95 chemotherapy was instituted on 9 May 2014. On day 29 of induction chemotherapy he was admitted to hospital as a result of sudden onset of seizures. He had involuntary clonic movements on the left side of the body with a loss of consciousness lasting 10 minutes; the seizures were aborted by diazepam. Immediate computerized tomography (CT) of the brain was carried out to rule out a bleed.

Computerized tomography of the brain showed evidence of multiple hypodense shadows in the right parietal occipital region with ill-defined margins and minimal perifocal oedema causing a compression effect on the right occipital horn of the lateral ventricles and effacement of the nearby sulci and gyri. Another faint hypodense shadow was seen in the left occipital region.

With the advice of the neurologist, we started him on a course of levetiracetam at 10 mg/kg once a day. The findings of subsequent magnetic resonance imaging of the brain were consistent with posterior reversible encephalopathy syndrome.

He continued to have intermittent episodes of seizures with hallucinations (visual and auditory). The dose of levetiracetam was hence increased to 10 mg/kg twice a day. On the second day after increasing the dose, he developed throat pain, progressing to grade IV oral mucositis in the following 96 hours, which was managed symptomatically. The blood counts recovered with an absolute neutrophil count of 1400/mm3. The seizures stopped, but he continued to experience hallucinations.

On reviewing the literature we could not find any reports of mucositis and hallucinations associated with the use of levetiracetam in children; however, the product insert information did mention these as rare side effects.

Owing to the adverse symptoms, we discontinued this medication and within 72 hours all of his symptoms had resolved. No further antiepileptic medication was given.

The end of induction bone marrow test showed that his disease was in remission. We hence continued chemotherapy as per the protocol, which he tolerated very well.


Levetiracetam has often been used for seizures in children with cancer because it has fewer reported side effects and is compatible with chemotherapy. We found severe mucositis with psychosis in an Emirati child with leukaemia who was receiving chemotherapy, symptoms that were resolved with the discontinuation of levetiracetam.

This is the first reported case in the literature of a link between severe mucositis with psychosis and levetiracetam in a Middle Eastern child with leukaemia.



Lynch B, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004; 101:9861–6.


Ramael S, Daoust A, Otoul C, et al. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia 2006; 47:1128–35.


Ramael S, De Smedt F, Toublanc N, et al. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Clin Ther 2006; 28:734–44.


Weinstock A, Ruiz M, Gerard D, et al. Prospective open-label, single-arm, multicenter, safety, tolerability, and pharmacokinetic studies of intravenous levetiracetam in children with epilepsy. J Child Neurol 2013; 28:1423–9.


Soni S, Skeens M, Termuhlen AM, Bajwa RP, Gross TG, Pai V. Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation. Pediatr Blood Cancer 2012; 59:762–4.

Comments on this article

View all comments  |  Add comment 

Home  Editorial Board  Search  Current Issue  Archive Issues  Announcements  Aims & Scope  About the Journal  How to Submit  Contact Us
Find out how to become a part of the HMJ  |   CLICK HERE >>
© Copyright 2012 - 2013 HMJ - HAMDAN Medical Journal. All Rights Reserved         Website Developed By Cedar Solutions INDIA